Correcting a genetic defect before birth sounds like a great idea, but I'm uncomfortable with how we get there.
FDA regulator Paul T. Hardy blew the whistle on problems with a Kodak mammography system — and got fired for his trouble. Here's what happened next.
As investigators finally trace a deadly listeria outbreak to melons from a Colorado packing shed, food safety expert Douglas Powell offers timely advice on covering food safety issues.
A new company aims to clean up the FDA's messy data for reporting drug adverse events and market it to pharma and other businesses. Health reporters can benefit from the company's work, too.
Why is the FDA'S adverse events drug database in such a shambles? Scientist Keith Hoffman explains — and talks about how his company has found a business opportunity in that messy data.
A new start-up is mining the FDA's adverse event data for medications and finding potentially dangerous patterns that the regulatory agency hasn't addressed — but should.
Shannon Brownlee offers a not-so-modest proposal for universities to stamp out pharma ghostwriting benefiting researchers.
Millions of American women were put on hormone replacement therapy before science evaluated the benefits and harms. Will men over 45 try testosterone replacement therapy too? Aggressive marketing of testosterone is on the rise.
A new reporting project will focus on community health challenges facing predominantly Latino communities in Chicago and the Midwest.
After 60+ years of smoking, my mother-in-law’s lungs were surely a toxic wasteland, yet nothing would make her quit. Journalist Ricki Lewis examines the risks and benefits of Chantix and highlights a new way to get smokers to quit: texting.
